Alivus Life Sciences Limited reported a net profit of ₹160 crore for the quarter ended June 30, 2026, supported by robust revenue growth and expanding margins. The company’s revenue from operations stood at ₹640 crore, marking a 6.4% year-on-year increase, while EBITDA reached ₹234 crore, up 29.1% year-on-year. This financial performance underscores the resilience of its diversified portfolio, particularly as the non-GPL segment delivered strong growth that counterbalanced significant headwinds in the GPL business.

The earnings call, held on July 31, 2026, highlighted a sharp divergence in business segments. While the GPL business declined by 52.6% year-on-year due to inventory rationalization, the non-GPL business surged by 26.5% year-on-year, driven by successful new product launches and strong demand across geographies. Management emphasized that this diversification has strengthened the revenue base, creating a platform for sustainable growth despite near-term volatility in specific segments.

Financial Performance Highlights

Gross margins improved to 60.2%, an increase of 510 basis points year-on-year, attributed to a favorable product mix, new launches, and operational efficiencies. EBITDA margins expanded by 650 basis points to 36.6%, further boosted by forex gains. Chronic therapies anchored the top line, accounting for 74% of revenue, with CVS and CNS contributing 58% collectively.

Operational Updates and Guidance

Dr. Yasir Rawjee, Managing Director and CEO, noted that while GPL growth is expected to remain flattish in FY '27, the business is historically weighted towards the second half, suggesting a stronger H2 performance. The CDMO business recorded 3.8% year-on-year growth, with management expecting momentum to build in the second half from newly added projects. Two new CDMO contracts are expected to close in early H2 FY '27.

On the capital expenditure front, Solapur Phase 1 is progressing with a slight delay but is expected to be operational in early Q3 FY '27. Construction at the Talaja R&D center has begun in earnest. The company incurred capex of ₹85 crore in the quarter and expects total capex of approximately ₹540 crore for FY '27. Alivus remains debt-free, with cash and cash equivalents including short-term investments totaling ₹880 crore as of June 30, 2026.

What the Numbers Show

The expansion in EBITDA margins to 36.6% significantly outpaces the 6.4% revenue growth, indicating a strong operating leverage effect from new high-margin launches and process improvements. However, management cautioned that raw material price increases, partly linked to geopolitical tensions, pose a risk to sustaining these peak margins. Consequently, the FY '27 EBITDA margin guidance is conservatively set at 30% to 32%, although management indicated potential for up to 34% if steady-state conditions prevail. This suggests that while current profitability is robust, future margin stability will depend on the company’s ability to pass on cost increases to customers amidst volatile input prices.

R&D expenditure stood at ₹24 crore, or 3.7% of sales, with management targeting a steady-state spend of around 4%. The pipeline remains robust with 617 DMF and CEP filings globally. The high-potent API portfolio includes 29 products in the active grid, addressing a total addressable market of $82 billion, with commercialization expected to gain traction from FY '28 onwards.

Alivus Life Sciences has fixed Tuesday, September 1, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹5 per equity share for the financial year ended March 31, 2026. This distribution, recommended by the Board of Directors on May 14, 2026, requires approval from shareholders at the Fifteenth Annual General Meeting (AGM) scheduled for Tuesday, September 8, 2026. If approved, the dividend will be paid on or after Friday, September 11, 2026, subject to applicable tax deductions at source.

The company notified the Bombay Stock Exchange and the National Stock Exchange of India Ltd regarding the AGM and record date in compliance with Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The AGM will be conducted via Video Conferencing or Other Audio-Visual Means (OAVM) at 03:00 pm IST, adhering to circulars issued by the Ministry of Corporate Affairs and SEBI.

Dividend Entitlement and Payment Details

Shareholders holding equity shares of ₹2 each will be eligible for the dividend based on their holdings as of the close of business hours on the record date. The payment mechanism differs slightly for dematerialized and physical holdings:

The company emphasized that the dividend is subject to deduction of tax at source. For shareholders holding shares in dematerialized form, the entitlement is determined by the data provided by the depositories. For those holding physical shares, valid transmission or transposition requests must be processed by the record date.

Key Dates and Compliance

The timeline for the dividend process is structured around the AGM approval. The Board’s recommendation was made on May 14, 2026, establishing the proposed payout amount. The subsequent fixing of the record date on August 6, 2026, ensures that shareholders have clear visibility on eligibility criteria before the general meeting.

The Fifteenth AGM serves as the final approval mechanism for this financial distribution. Conducting the meeting through VC/OAVM aligns with current regulatory frameworks allowing remote participation. The company secretary and compliance officer, Rudalf Joseph Corriea, signed the intimation, confirming adherence to listing obligations.

What the Numbers Show

The declaration of a ₹5 per share final dividend represents a tangible return to shareholders for FY26. With the face value of the equity share standing at ₹2, the dividend yield calculation depends on the market price at the time of investment. The fixed record date of September 1, 2026, creates a definitive cutoff for ownership, ensuring that only those holding shares through that date receive the payout. This structure provides clarity for investors planning their positions ahead of the AGM on September 8, 2026.